Oveporexton
Oveporexton, sold under the brand name Orzeyful, is a medication used for the treatment of narcolepsy type 1.
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Oveporexton, sold under the brand name Orzeyful, is a medication used for the treatment of narcolepsy type 1. It is taken by mouth. The most common side effects include insomnia, increased urinary frequency, urgency to urinate, and increased saliva production.
Oveporexton is an orexin OX 2 receptor agonist. Oveporexton was approved for medical use in China in July 2026, and in the United States in August 2026. It is recommended for scheduling under the Controlled Substances Act and will be lawful to market in the US following the scheduling decision issued by the Drug Enforcement Administration.
Contraindications
The only listed absolute contraindication of oveporexton is combination with strong CYP3A4 inhibitors.
Overdose
There is no specific antidote for oveporexton overdose.
Interactions
Oveporexton is primarily metabolized by the cytochrome P450 enzyme CYP3A4. As such, CYP3A4 inhibitors and inducers can alter oveporexton exposure and hence result in interactions when combined with oveporexton. Strong CYP3A4 inhibitors are contraindicated with oveporexton, while dose reduction is warranted with moderate CYP3A4 inhibitors.
Use with moderate to strong CYP3A4 inducers should be avoided. No clinically meaningful interactions are expected with weak CYP3A4 inhibitors and inducers. Examples of moderate to strong CYP3A4 inhibitors include itraconazole and fluconazole.
Examples of moderate to strong CYP3A4 inducers include phenytoin. Oveporexton does not appear to inhibit or induce various cytochrome P450 enzymes itself.
Pharmacodynamics
Oveporexton acts as a selective agonist of the orexin OX 2 receptor. Oveporexton has wakefulness-promoting effects in animals, including in rodents and monkeys. In addition, oveporexton has been found to be effective in the treatment of narcolepsy and cataplexy in phase 3 clinical trials in humans.
Oveporexton is a first-in-class medication and targets the root symptomatic cause of narcolepsy type 1 by remediating the orexin (hypocretin) deficiency that is present in the condition.
Pharmacokinetics
The disposition of oveporexton is biexponential and it has an elimination half-life of 16 to 24 hours in humans. The FDA label gives a more specific mean terminal elimination half-life of 23.2 hours.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1379069996 under CC BY-SA 4.0; modifications have been made.